CN112135618A - 体内介导免疫应答的nk和dc细胞的扩增 - Google Patents

体内介导免疫应答的nk和dc细胞的扩增 Download PDF

Info

Publication number
CN112135618A
CN112135618A CN201980022329.9A CN201980022329A CN112135618A CN 112135618 A CN112135618 A CN 112135618A CN 201980022329 A CN201980022329 A CN 201980022329A CN 112135618 A CN112135618 A CN 112135618A
Authority
CN
China
Prior art keywords
cells
optionally
substituents
alkyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980022329.9A
Other languages
English (en)
Chinese (zh)
Inventor
G·索瓦若
S·科亨
J·罗伊
S·拉汉斯
J-S·德利斯勒
J·查格劳伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Universite de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal filed Critical Universite de Montreal
Publication of CN112135618A publication Critical patent/CN112135618A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1315—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from cardiomyocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980022329.9A 2018-02-20 2019-02-20 体内介导免疫应答的nk和dc细胞的扩增 Pending CN112135618A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632733P 2018-02-20 2018-02-20
US62/632,733 2018-02-20
PCT/CA2019/050208 WO2019161494A1 (en) 2018-02-20 2019-02-20 Expansion of nk and dc cells in vivo mediating immune response

Publications (1)

Publication Number Publication Date
CN112135618A true CN112135618A (zh) 2020-12-25

Family

ID=67687479

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980022329.9A Pending CN112135618A (zh) 2018-02-20 2019-02-20 体内介导免疫应答的nk和dc细胞的扩增

Country Status (6)

Country Link
US (1) US12011460B2 (https=)
EP (1) EP3755355A4 (https=)
JP (1) JP7467358B2 (https=)
CN (1) CN112135618A (https=)
CA (1) CA3091865A1 (https=)
WO (1) WO2019161494A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109212187A (zh) * 2018-09-06 2019-01-15 东华大学 一种检测多环芳烃的类酶联免疫试剂盒及其应用
CN113350356A (zh) * 2021-05-26 2021-09-07 广东湛江海洋医药研究院 2,4,7-三取代嘧啶并吲哚化合物抗肿瘤耐药作用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112851678B (zh) * 2019-11-28 2022-04-19 广东医科大学 2，4，7-三取代嘧啶并吲哚化合物抗肿瘤转移作用
CN112851679B (zh) * 2019-11-28 2022-03-25 广东医科大学 2，4，7-三取代嘧啶并吲哚化合物抗肿瘤作用
AU2020409437A1 (en) * 2019-12-18 2022-07-14 Universite De Montreal Modulators of Cullin 3 adaptor KBTBD4 as anti-cancer compounds

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018297A1 (en) * 1995-11-13 1997-05-22 The Regents Of The University Of Michigan Functional human hematopoietic cells
WO2007065927A1 (en) * 2005-12-07 2007-06-14 Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2009040666A2 (en) * 2007-05-25 2009-04-02 Sun Uk Song Treatment of graft-versus-host disease
WO2013086436A1 (en) * 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2016109661A1 (en) * 2014-12-31 2016-07-07 Anthrogenesis Corporation Natural killer cells and uses thereof
CN106414445A (zh) * 2014-04-22 2017-02-15 蒙特利尔大学 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用
WO2017066530A1 (en) * 2015-10-15 2017-04-20 Anthrogensis Corporation Natural killer cells and ilc3 cells and uses thereof
WO2017205977A1 (en) * 2016-06-01 2017-12-07 Universite De Montreal Selection of human hematopoetic stem cells using epcr
AU2018200424A1 (en) * 2010-07-13 2018-02-08 Anthrogenesis Corporation Methods of generating natural killer cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1442039A1 (en) 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090029982A1 (en) 2005-04-28 2009-01-29 Supergen, Inc. Protein kinase inhibitors
WO2008055233A1 (en) 2006-10-31 2008-05-08 Supergen, Inc. Protein kinase inhibitors
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
EP2170886A1 (en) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
WO2011056739A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Compounds and methods
PT2807165T (pt) 2012-01-27 2019-07-12 Univ Montreal Derivados de pirimido[4,5-b]indole e sua utilização na expansão de células estaminais hematopoiéticas
JP6460991B2 (ja) 2012-09-12 2019-01-30 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗菌剤として使用するための三環式ジャイレース阻害剤
WO2017120597A1 (en) 2016-01-07 2017-07-13 Ripple Foods, Pbc Product analogs or components of such analogs and processes for making same

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018297A1 (en) * 1995-11-13 1997-05-22 The Regents Of The University Of Michigan Functional human hematopoietic cells
WO2007065927A1 (en) * 2005-12-07 2007-06-14 Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2009040666A2 (en) * 2007-05-25 2009-04-02 Sun Uk Song Treatment of graft-versus-host disease
AU2018200424A1 (en) * 2010-07-13 2018-02-08 Anthrogenesis Corporation Methods of generating natural killer cells
WO2013086436A1 (en) * 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
CN106414445A (zh) * 2014-04-22 2017-02-15 蒙特利尔大学 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用
WO2016109661A1 (en) * 2014-12-31 2016-07-07 Anthrogenesis Corporation Natural killer cells and uses thereof
WO2017066530A1 (en) * 2015-10-15 2017-04-20 Anthrogensis Corporation Natural killer cells and ilc3 cells and uses thereof
WO2017205977A1 (en) * 2016-06-01 2017-12-07 Universite De Montreal Selection of human hematopoetic stem cells using epcr

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CATHERINE M. SAWAI等: "Hematopoietic Stem Cells Are the Major Source of Multilineage Hematopoiesis in Adult Animals", 《IMMUNITY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109212187A (zh) * 2018-09-06 2019-01-15 东华大学 一种检测多环芳烃的类酶联免疫试剂盒及其应用
CN109212187B (zh) * 2018-09-06 2022-01-11 东华大学 一种检测多环芳烃的类酶联免疫试剂盒及其应用
CN113350356A (zh) * 2021-05-26 2021-09-07 广东湛江海洋医药研究院 2,4,7-三取代嘧啶并吲哚化合物抗肿瘤耐药作用

Also Published As

Publication number Publication date
CA3091865A1 (en) 2019-08-29
US20210085714A1 (en) 2021-03-25
US12011460B2 (en) 2024-06-18
EP3755355A1 (en) 2020-12-30
JP7467358B2 (ja) 2024-04-15
EP3755355A4 (en) 2022-01-05
JP2021521262A (ja) 2021-08-26
WO2019161494A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
CN112135618A (zh) 体内介导免疫应答的nk和dc细胞的扩增
US12036241B2 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
US9409906B2 (en) Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells
US11098284B2 (en) Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
AU2012347534B2 (en) Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2020051207A2 (en) Aryl hydrocarbon receptor antagonists and methods of use
CA3152281A1 (en) Cbl inhibitors and compositions for expansion of immune cells
EP2836214B1 (en) Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
US20110052547A1 (en) Rapamycin-resistant t cells and therapeutic uses thereof
CN104873540A (zh) 多潜能成体祖细胞的免疫调节特性及其用途
JP2008517948A5 (https=)
US20080305079A1 (en) Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity
CN108473949A (zh) 扩增的造血干细胞/祖细胞群体的用途
WO2003039232A2 (en) Endothelial cell derived hemotopoietic growth factor
CN111712262A (zh) 用于动员造血干细胞和祖细胞的给药方案
US20230011889A1 (en) Genetically engineered double negative t cells as an adoptive cellular therapy
Perico et al. A modern view of transplant immunology and immunosuppression
JP2022505615A (ja) 造血幹・前駆細胞移植療法の方法
WO2005003335A9 (en) Rapamycin resistant t cells and therapeutic uses thereof
JP2021510150A (ja) 造血幹細胞および前駆細胞の増幅ならびに遺伝性代謝障害の処置のための組成物および方法
CA3237288A1 (en) Phosphatase inhibitors as nk cells modulators for the treatment of cancer
WO2025172541A1 (en) New composition for improvement of bone marrow reconstitution and peripheral recovery of neutrophil and platelet counts
Klamer et al. Strategies to Improve Immune
Collins Jr Allogeneic bone marrow transplantation
HK1214166B (zh) 多潜能成体祖细胞的免疫调节特性及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20201225